Menu
Dr. Nadav has been a board member at Tevel from Series A. Dr. Nadav is an investor and a biopharma veteran. He has been with the investment firm TPG from 2007-2018, serving as Partner and Managing Director at the TPG Biotech fund in San Francisco. During his tenure at TPG, he led pharma and biotech deals across various geographies and stages of development. Currently he serves as Senior Advisor of TPG Biotech.
Prior to TPG, Dr. Nadav was Business Development Director at Eisai in New Jersey, where he evaluated and negotiated licensing and acquisition deals. Previously, Dr. Nadav worked for JJDC, the venture capital subsidiary of Johnson & Johnson. Earlier, he worked for Neurim Pharmaceuticals in a product development role.
Dr. Nadav holds a Ph.D. in Biochemistry, an M.Sc. magna cum laude, a B.Sc. magna cum laude, and an MBA from Tel Aviv University.
Representing TPG, Dr. Nadav was the lead investor and Chairman of the Board of Ultragenyx Pharmaceutical (Nasdaq: RARE) and Trevi Therapeutics. His other investments and board roles include Fusion Pharmaceuticals (Nasdaq: FUSN), Carisma Therapeutics, Collegium Pharmaceutical (Nasdaq: COLL), JCR Pharmaceuticals (a Japanese biopharma company, TSE: 4552), MacroGenics (Nasdaq: MGNX), ShangPharma (a China based CRO), and Eden Springs / Mey Eden. He is also a member at the Investment Committee at Lagunita Biosciences, a healthcare investment company and incubator.
